FDA Seeks ‘Phantom’ Retina With An Eye Toward OCT Device Bench Testing
This article was originally published in The Gray Sheet
Executive Summary
After receiving a grant last year, CDRH researchers are working toward a consensus phantom eye model to allow for standardized bench testing for optical coherence tomography device submissions.
You may also be interested in...
ASCO - Servier’s Vorasidenib Puts The Brakes On Brain Cancer In INDIGO
Servier’s targeted therapy, vorasidenib, can effectively delay the need for more drastic treatment in patients with low-grade glioma, but increases in liver enzymes including two cases of Hy’s law have cast some shade over the INDIGO data.
ASCO 2023 – A Role For Immuno-Oncology In Ovarian Cancer At Last?
AstraZeneca’s Duo-O trial suggests that excluding Brca-positive patients could be the key to Imfinzi’s apparent success in ovarian cancer.
ASCO 2023 – Pfizer Pushes Forward In Drug-Resistant Breast Cancer
While Ibrance has been bested by class rivals Pfizer is working on projects that might overcome CDK4/6 inhibitor resistance, although it is not alone.